SCHIFF ANDREW N 4

What Happened Andrew N. Schiff, a director of Monte Rosa Therapeutics, was granted a derivative award on 2026-06-11 covering 25,800 shares at $0.00 per share (transaction code A — award/grant). This filing reports an option-like award (derivative) rather than an open-market purchase or sale; no cash was paid in connection with the grant.

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-12 (Form 4 filed promptly).
• Transaction type: Award/Grant (code A) of 25,800 shares; exercise/acquisition price reported as $0.00.
• Total immediate cash value reported: $0 (derivative award; value realized depends on future vesting/exercise and stock price).
• Vesting: The award vests in full upon the earlier of (i) June 11, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service (footnote F1).
• Shares owned after transaction: not disclosed in the excerpt of this filing.
• Not a sale or exercise; no 10b5-1 plan, tax withholding, or cashless exercise noted.

Context This was a compensatory award to a director that vests in the future — common for board compensation. Because it is a derivative award with a vesting condition, it does not represent an immediate market purchase or sale and should be interpreted as part of standard director pay rather than a direct bullish or bearish trade signal.